Citizens Maintains Market Outperform on DBV Technologies, Raises Price Target to $47
3/27/2026
Impact: 70
Healthcare
Citizens analyst Jonathan Wolleben has maintained a Market Outperform rating on DBV Technologies (NASDAQ: DBVT) and increased the price target from $45 to $47.
AI summary, not financial advice
Share: